Furthermore, in patients with fully resected in stage IIIA NSCLC, the introduction of third-generation EGFR-TKI osimertinib did not yield significantly greater survival benefits compared to first-generation drugs. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.